Developer docs
API playgroundTry for free, no card

Search company profiles

Aces Diagnostics

Full company profile

uuid0008kxn

Namestring
Aces Diagnostics
Legal namestring
Aces Diagnostics, Inc.
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPortola Valley, United States
HQ citystring
Portola Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
Lyme disease diagnostics, blood diagnostic testing, multiplexed immunoassay, clinical laboratory testing, infectious disease detection
Industry3 codes
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Clinical Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

Aces Diagnostics plans to generate revenue through a single blood test for Lyme disease detection. The test will be offered via clinical laboratory partnerships, with commercial launch anticipated in 2027. As a diagnostic test, revenue is expected to come from test fees per sample processed.

acesdiagnostics.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1LYMESEEK
Description

A clinically validated blood test using multiplexed immunoassay technology combined with machine learning algorithms for improved Lyme disease detection across all stages of disease.

acesdiagnostics.com
Core offering1 text field

Aces Diagnostics develops LYMESEEK, a single blood test that combines proprietary biomarkers with machine learning algorithms to enable earlier, more accurate Lyme disease detection across all stages of infection. The test is designed to run on existing clinical laboratory equipment without requiring special instrumentation and is being validated for FDA regulatory clearance with commercial launch anticipated in 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Boston Strategic Partners projects LYMESEEK could reduce Lyme-related healthcare costs by $3.2 Billion annually through earlier diagnosis and intervention
+2 more records
Product overview1 text field

Aces Diagnostics offers a single unified product: LYMESEEK™, a multiplexed immunoassay blood test for Lyme disease detection. The test combines proprietary biomarkers with machine learning algorithms and is designed to run on existing clinical laboratory equipment. Commercial launch is anticipated in 2027 pending FDA regulatory clearance.

Product and service1 record
1LYMESEEK
CategoryClinical Diagnostics
Description

A single blood test that combines proprietary biomarkers with machine learning to enable earlier, more accurate Lyme disease detection across all stages of infection. Validated on more than 1,000 clinical samples from U.S. and European populations demonstrating greater than 90% accuracy. Designed to run on existing clinical laboratory equipment, requiring only one blood draw.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Protavio
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-16
Description

Partnership with Protavio to develop the LymeSeek diagnostic test for Lyme disease. The collaboration aims to advance the test towards commercialization including FDA submission. The test uses multiplexed immunoassay technology and machine-learning algorithms to improve early detection accuracy.

prnewswire.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-16
Description

Partnership with Repado to develop the LymeSeek diagnostic test for Lyme disease. The collaboration aims to advance the test towards commercialization including FDA submission. The test uses multiplexed immunoassay technology and machine-learning algorithms to improve early detection accuracy.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Quest Diagnostics is a major reference laboratory offering Lyme disease serology testing services to physicians and health systems; it represents a potential channel partner and competitor for Aces' clinical laboratory partnership model.

TypeEmerging player
Description

T2 Biosystems is a small, clinical-stage diagnostics company focused on rapid direct-from-blood detection of infectious disease pathogens. Comparable to Aces as an emerging infectious disease diagnostics player navigating the FDA and clinical launch path.

TypeBroad incumbent
Description

QIAGEN is a global molecular diagnostics and sample-prep company with broad infectious disease test menus. While not focused on Lyme, its QIAstat-Dx and molecular diagnostics platforms represent a broader competitive threat in infectious disease testing.

TypeDirect peer
Description

Oxford Immunotec (part of Revvity/PerkinElmer) develops specialized immunology and infectious disease diagnostics, including historically in tick-borne disease testing. Comparable to Aces as a specialty infectious disease diagnostics company.

TypeBroad incumbent
Description

Labcorp is one of the largest clinical reference laboratories in the U.S. and offers Lyme disease testing services, representing both a potential commercialization partner and an entrenched competitor to LYMESEEK.

TypeDirect peer
Description

EUROIMMUN, now part of Revvity (formerly PerkinElmer), offers a broad menu of autoimmune and infectious disease serology tests including Lyme disease immunoassays, directly overlapping with LYMESEEK's multiplexed serology approach.

TypeBroad incumbent
Description

bioMérieux is a global in vitro diagnostics company with broad infectious disease menus; comparable as a large IVD incumbent whose diagnostic platforms could be used for Lyme serology and molecular testing.

TypeBroad incumbent
Description

Bio-Rad is a large, established life science and clinical diagnostics company that produces quality controls, immunoassay instruments, and infectious disease test kits. Its BioPlex 2200 Lyme menu directly competes with LYMESEEK.

TypeDirect peer
Description

Trinity Biotech is a direct peer as a developer and manufacturer of diagnostic test kits for infectious diseases including Lyme disease (e.g., the MarDx line). It is the most directly comparable commercial Lyme diagnostics competitor to Aces' LYMESEEK.

TypeDirect peer
Description

Zeus Scientific develops and markets immunoassay diagnostic test kits, including FDA-cleared Lyme disease serology tests, directly competing with Aces in the clinical Lyme diagnostics market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aces Diagnostics

Clinical Diagnosticsacesdiagnostics.com

Aces Diagnostics firmographics

Firmographics
Name
Aces Diagnostics
Legal name
Aces Diagnostics, Inc.
Website
https://acesdiagnostics.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Aces Diagnostics industry classification

Industry
Product category
Clinical Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)

Keywords

  • Lyme disease diagnostics
  • Blood diagnostic testing
  • Multiplexed immunoassay
  • Clinical laboratory testing
  • Infectious disease detection

Where Aces Diagnostics is headquartered

Location

Headquarters

HQ city
Portola Valley
HQ country
United States
HQ region
North America

Markets served

Aces Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Testing Services: Aces Diagnostics plans to generate revenue through a single blood test for Lyme disease detection. The test will be offered via clinical laboratory partnerships, with commercial launch anticipated in 2027. As a diagnostic test, revenue is expected to come from test fees per sample processed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Aces Diagnostics product offering

Product offering

Core offering

Aces Diagnostics develops LYMESEEK, a single blood test that combines proprietary biomarkers with machine learning algorithms to enable earlier, more accurate Lyme disease detection across all stages of infection. The test is designed to run on existing clinical laboratory equipment without requiring special instrumentation and is being validated for FDA regulatory clearance with commercial launch anticipated in 2027.

Product overview

Aces Diagnostics offers a single unified product: LYMESEEK™, a multiplexed immunoassay blood test for Lyme disease detection. The test combines proprietary biomarkers with machine learning algorithms and is designed to run on existing clinical laboratory equipment. Commercial launch is anticipated in 2027 pending FDA regulatory clearance.

Differentiator

Problem solved

Functional benefit

Brands

  • LYMESEEK: A clinically validated blood test using multiplexed immunoassay technology combined with machine learning algorithms for improved Lyme disease detection across all stages of disease.

Products and services

  • LYMESEEK A single blood test that combines proprietary biomarkers with machine learning to enable earlier, more accurate Lyme disease detection across all stages of infection. Validated on more than 1,000 clinical samples from U.S. and European populations demonstrating greater than 90% accuracy. Designed to run on existing clinical laboratory equipment, requiring only one blood draw.

Quantifiable outcome

  • Boston Strategic Partners projects LYMESEEK could reduce Lyme-related healthcare costs by $3.2 Billion annually through earlier diagnosis and intervention
  • +2 more outcomes

Companies that use Aces Diagnostics

Customer profile

Segments4 records

Ideal customer profiles3 records

Aces Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Aces Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ProtaviocoreTechnology or Integration · 16 December 2025Partnership with Protavio to develop the LymeSeek diagnostic test for Lyme disease. The collaboration aims to advance the test towards commercialization including FDA submission. The test uses multiplexed immunoassay technology and machine-learning algorithms to improve early detection accuracy.
  • RepadocoreTechnology or Integration · 16 December 2025Partnership with Repado to develop the LymeSeek diagnostic test for Lyme disease. The collaboration aims to advance the test towards commercialization including FDA submission. The test uses multiplexed immunoassay technology and machine-learning algorithms to improve early detection accuracy.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Aces Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is a major reference laboratory offering Lyme disease serology testing services to physicians and health systems; it represents a potential channel partner and competitor for Aces' clinical laboratory partnership model.
  • QIAGEN: QIAGEN is a global molecular diagnostics and sample-prep company with broad infectious disease test menus. While not focused on Lyme, its QIAstat-Dx and molecular diagnostics platforms represent a broader competitive threat in infectious disease testing.
  • Labcorp: Labcorp is one of the largest clinical reference laboratories in the U.S. and offers Lyme disease testing services, representing both a potential commercialization partner and an entrenched competitor to LYMESEEK.
  • Mérieux NutriSciences (bioMérieux): bioMérieux is a global in vitro diagnostics company with broad infectious disease menus; comparable as a large IVD incumbent whose diagnostic platforms could be used for Lyme serology and molecular testing.
  • Bio-Rad Laboratories: Bio-Rad is a large, established life science and clinical diagnostics company that produces quality controls, immunoassay instruments, and infectious disease test kits. Its BioPlex 2200 Lyme menu directly competes with LYMESEEK.

Emerging players

  • T2 Biosystems: T2 Biosystems is a small, clinical-stage diagnostics company focused on rapid direct-from-blood detection of infectious disease pathogens. Comparable to Aces as an emerging infectious disease diagnostics player navigating the FDA and clinical launch path.

Direct peers

  • Oxford Immunotec: Oxford Immunotec (part of Revvity/PerkinElmer) develops specialized immunology and infectious disease diagnostics, including historically in tick-borne disease testing. Comparable to Aces as a specialty infectious disease diagnostics company.
  • EUROIMMUN (Revvity): EUROIMMUN, now part of Revvity (formerly PerkinElmer), offers a broad menu of autoimmune and infectious disease serology tests including Lyme disease immunoassays, directly overlapping with LYMESEEK's multiplexed serology approach.
  • Trinity Biotech: Trinity Biotech is a direct peer as a developer and manufacturer of diagnostic test kits for infectious diseases including Lyme disease (e.g., the MarDx line). It is the most directly comparable commercial Lyme diagnostics competitor to Aces' LYMESEEK.
  • Zeus Scientific: Zeus Scientific develops and markets immunoassay diagnostic test kits, including FDA-cleared Lyme disease serology tests, directly competing with Aces in the clinical Lyme diagnostics market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Aces Diagnostics social profiles

Digital presence

Aces Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aces Diagnostics leadership team

Management profile

Number of profiles

Profiles9 records

Aces Diagnostics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aces Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aces Diagnostics

What does Aces Diagnostics do?

Aces Diagnostics develops LYMESEEK, a single blood test that combines proprietary biomarkers with machine learning algorithms to enable earlier, more accurate Lyme disease detection across all stages of infection. The test is designed to run on existing clinical laboratory equipment without requiring special instrumentation and is being validated for FDA regulatory clearance with commercial launch anticipated in 2027.

Is Aces Diagnostics a public or private company?

Aces Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aces Diagnostics founded?

Aces Diagnostics was founded in 2024. It employs 1 to 10 people.

Where is Aces Diagnostics based?

Aces Diagnostics is headquartered in Portola Valley, United States, in the North America region.

How does Aces Diagnostics make money?

One revenue line is on record: diagnostic Testing Services.

Who are Aces Diagnostics's main competitors?

Broad incumbents on record are Quest Diagnostics, QIAGEN, Labcorp, Mérieux NutriSciences (bioMérieux) and Bio-Rad Laboratories. T2 Biosystems is listed as an emerging player. Direct peers are Oxford Immunotec, EUROIMMUN (Revvity), Trinity Biotech and Zeus Scientific.

Does Aces Diagnostics have an API?

No public API is recorded for Aces Diagnostics.

What industry is Aces Diagnostics in?

Aces Diagnostics's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireACES Diagnostics Research Demonstrates Potential of LymeSeek™ to Improve Detection of Early Lyme DiseaseA peer-reviewed study in the Journal of Clinical Microbiology reports LymeSeek, a single-tier Lyme test, achieved over 90% sensitivity across disease stages. The company plans clinical trials in October 2026 and targets FDA clearance and market availability by early Q2 2027.AijournNew Economic Modeling Shows Improved Lyme Disease Diagnostics Could Cut U.S. Lyme Healthcare Costs by 41.5%Aces Diagnostics announced findings from an independent health economics analysis showing that its LymeSeek diagnostic test could reduce annual Lyme disease-related U.S. healthcare costs by 41.5%, from $7.65 billion to $4.48 billion, with misdiagnosis-related costs declining 79.53%. The analysis, conducted with Boston Strategic Partners using a budget impact model simulating a national U.S. patient cohort, found that early diagnosis at the localized stage more than doubled (+105.06%) and false-negative results fell 79.65%. The findings will be presented at the ADLM 2026 Annual Meeting by Holly Ahern, Chief Scientific Officer of Aces Diagnostics.PR NewswireNew Economic Modeling Shows Improved Lyme Disease Diagnostics Could Cut U.S. Lyme Healthcare Costs by 41.5%Aces Diagnostics announced findings from an independent health economics analysis showing that its higher-sensitivity Lyme disease diagnostic, LymeSeek, could reduce annual LD-related U.S. healthcare costs by 41.5%, from $7.65 billion to $4.48 billion. The analysis, conducted with Boston Strategic Partners, projects that early diagnosis cases would more than double (+105.06%) and false-negative results would fall 79.65% under LymeSeek-based testing compared to standard two-tier serologic testing. The findings will be presented at the ADLM 2026 Annual Meeting on July 27, 2026.PR NewswireAces Diagnostics Announces Key Development Partnerships for Novel LymeSeek™ TestAces Diagnostics Inc. announced new development partnerships with Protavio and Repado to advance the commercialization of its LymeSeek™ diagnostic test. Protavio will develop the IVD-grade test kit while Repado is building the analysis software incorporating the company's machine-learning algorithm.